News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website


Study finds two distinct subtypes in pediatric diffuse intrinsic pontine gliomas


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

Excellent work.. Identifying the pathways involved is the first step toward the cure.

THis was another research project that was funded by the Musella Foundation!



Website: http://www.news-medical.net/news/20131204/Study-finds-two-distinct-subtypes-in-pediatric-diffuse-intrinsic-pontine-gliomas.aspx

Posted on: 12/05/2013

Study finds two distinct subtypes in pediatric diffuse intrinsic pontine gliomas
Published on December 4, 2013 at 4:00 AM · No Comments
 
 
 
Children's National researcher, Javad Nazarian, PhD, authored a new study entitled, "Comparative Multidimensional Molecular Analyses of Pediatric Diffuse Intrinsic Pontine Glioma Reveals Distinct Molecular Subtypes." The study found, for the first time, two distinct subtypes in pediatric diffuse intrinsic pontine gliomas (DIPG). It was published online in Acta Neuropathologica, a leading journal on pathology and pathogenesis of neurological disease.
 
This project was the first time researchers conducted a detailed analysis of proteome, transcriptome, methylome, and Histone H3 mutation profiles of DIPG specimens. One of the major results of the study was the discovery of two distinct subtypes of DIPGs and the identification of potential molecular pathways that lead to poorer overall survival of patients with histone 3 mutations.
 
DIPG is an aggressive tumor of the brain stem that cannot be surgically removed and is typically not biopsied due to the invasiveness of the procedure. For these reasons, a lack of tissue samples have contributed to a limited understanding of the tumor biology and hindered the development of treatments to improve survival rates.
 
"Pediatric DIPGs are almost always lethal, and most children do not survive beyond 18 months with this type of tumor," said Dr. Nazarian. "Our results have shown that a multidimensional molecular analysis can contribute to our understanding of DIPGs and guide future research for developing therapeutics."
 
Further study and a larger cohort of DIPG specimens are needed to identify all possible subtypes of DIPGs. Children's Research Institute (CRI) at Children's National Health System has generated the only published data on protein profiling of DIPGs. This is the third study on DIPG published by CRI.
 
Source: Children's National Medical Center
 
Currently rated 5.0 by 1 people

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740